Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-19
2011-04-19
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S293000
Reexamination Certificate
active
07928114
ABSTRACT:
Crystalline Forms of erlotinib are made. The crystalline materials are useful as pharmaceutical active agents in treating various cancers as well as in forming erlotinib salts.
REFERENCES:
patent: 5747498 (1998-05-01), Schnur et al.
patent: 2 302 965 (2000-09-01), None
patent: 1044969 (2000-12-01), None
patent: 0 817 775 (2001-09-01), None
patent: WO 99/55683 (1999-11-01), None
patent: WO 01/34574 (2001-05-01), None
patent: WO 2004/072049 (2004-08-01), None
Muncy Geissler Olds & Lowe, PLLC
Synthon BV
Willis Douglas M
Wilson James O
LandOfFree
Crystalline erlotinib does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline erlotinib, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline erlotinib will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694777